SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001753926-20-000326
Filing Date
2020-10-05
Accepted
2020-10-05 17:21:21
Documents
3
Group Members
AMIN NATHOOANSON ADVISORS INC.ANSON MANAGEMENT GP LLCBRUCE R. WINSONMOEZ KASSAM

Document Format Files

Seq Description Document Type Size
1 SC 13D g082041_sc13d.htm SC 13D 181085
2 EXHIBIT 99.1 g082041_ex99-1.htm EX-99.1 30626
3 EXHIBIT 99.2 g082041_ex99-2.htm EX-99.2 17563
  Complete submission text file 0001753926-20-000326.txt   231372
Mailing Address 655 MONTGOMERY STREET SUITE 900 SAN FRANCISCO CA 94111
Business Address 655 MONTGOMERY STREET SUITE 900 SAN FRANCISCO CA 94111 (408) 737-2734
Amarantus Bioscience Holdings, Inc. (Subject) CIK: 0001424812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-87050 | Film No.: 201224531
SIC: 2834 Pharmaceutical Preparations

Mailing Address 5950 BERKSHIRE LANE SUITE 210 DALLAS TX 75225
Business Address 5950 BERKSHIRE LANE SUITE 210 DALLAS TX 75225 214.866.0202
Anson Funds Management LP (Filed by) CIK: 0001491072 (see all company filings)

IRS No.: 300134498 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SC 13D